CMS launches its Medicare GLP-1 Bridge July 1, giving eligible Medicare Part D beneficiaries access to weight-loss GLP-1s at a $50 monthly copay through December 2027. For health systems and pharmacy leaders,

Millions of older Americans may have access for the first time to obesity drugs at a low price of $50 a month starting in July under a Medicare pilot program. While Medicare Part

A Michigan woman who owned a home care agency was convicted on charges relating to a $1.6 million scheme to defraud Medicare.

The GLP‑1 Bridge pilot program would allow Medicare to broadly cover weight‑loss versions of GLP‑1 medications, such as Wegovy.

The Trump administration has authorized a test program to see if the cannabis compound can ease some symptoms and reduce health care costs among older patients.

At the worst, you are charged for unpaid services, your credit is damaged, and your medical records are compromised.

Medicare, long banned from covering weight loss treatments, will now allow beneficiaries to get a GLP-1 prescription for $50 a month. It comes with caveats.

Learn who qualifies for Medicare’s GLP-1 Bridge, when $50 Wegovy and Zepbound access begins, and key rules beneficiaries need to know before July 2026.